JP2024523413A - ニューロパチーの治療のための併用療法 - Google Patents

ニューロパチーの治療のための併用療法 Download PDF

Info

Publication number
JP2024523413A
JP2024523413A JP2023577985A JP2023577985A JP2024523413A JP 2024523413 A JP2024523413 A JP 2024523413A JP 2023577985 A JP2023577985 A JP 2023577985A JP 2023577985 A JP2023577985 A JP 2023577985A JP 2024523413 A JP2024523413 A JP 2024523413A
Authority
JP
Japan
Prior art keywords
combination
scfa
gdnf
pharma
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523413A5 (cg-RX-API-DMAC7.html
Inventor
ロドルフ・ソレ
ニコラ・ピロン
Original Assignee
トランスフェルト・プラス・リミテッド・パートナーシップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランスフェルト・プラス・リミテッド・パートナーシップ filed Critical トランスフェルト・プラス・リミテッド・パートナーシップ
Publication of JP2024523413A publication Critical patent/JP2024523413A/ja
Publication of JP2024523413A5 publication Critical patent/JP2024523413A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/124—Acids containing four carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023577985A 2021-06-16 2022-06-15 ニューロパチーの治療のための併用療法 Pending JP2024523413A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163202549P 2021-06-16 2021-06-16
US63/202,549 2021-06-16
PCT/CA2022/050955 WO2022261765A1 (en) 2021-06-16 2022-06-15 Combination therapy for the treatment of enteric neuropathies

Publications (2)

Publication Number Publication Date
JP2024523413A true JP2024523413A (ja) 2024-06-28
JP2024523413A5 JP2024523413A5 (cg-RX-API-DMAC7.html) 2025-03-28

Family

ID=84526051

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577985A Pending JP2024523413A (ja) 2021-06-16 2022-06-15 ニューロパチーの治療のための併用療法

Country Status (8)

Country Link
US (1) US20240366723A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355354A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523413A (cg-RX-API-DMAC7.html)
KR (1) KR20240021837A (cg-RX-API-DMAC7.html)
CN (1) CN117615776A (cg-RX-API-DMAC7.html)
AU (1) AU2022294711A1 (cg-RX-API-DMAC7.html)
CA (1) CA3220781A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022261765A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110440A1 (en) * 2013-01-10 2014-07-17 Biogen Idec Ma Inc. Methods for improved production and recovery of recombinant proteins from eukaryotic cell cultures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160045487A1 (en) * 2013-03-27 2016-02-18 Childeren's Medical Center Corporation Compositions and methods for treating neuropathy
CA3162011A1 (en) * 2019-12-19 2021-06-24 Rodolphe SORET Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110440A1 (en) * 2013-01-10 2014-07-17 Biogen Idec Ma Inc. Methods for improved production and recovery of recombinant proteins from eukaryotic cell cultures

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. Vol.302, pp.G1373-1380, JPN6025052985, 2012, ISSN: 0005766103 *
GASTROENTEROLOGY, vol. Vol.159, pp.1824-1838, JPN6025052984, 2020, ISSN: 0005766102 *

Also Published As

Publication number Publication date
EP4355354A4 (en) 2025-04-09
WO2022261765A1 (en) 2022-12-22
CN117615776A (zh) 2024-02-27
AU2022294711A1 (en) 2023-12-21
US20240366723A1 (en) 2024-11-07
CA3220781A1 (en) 2022-12-22
EP4355354A1 (en) 2024-04-24
KR20240021837A (ko) 2024-02-19

Similar Documents

Publication Publication Date Title
US8772233B2 (en) Method for promoting regeneration of pancreatic beta-cells by administering neurturin
US20130029908A1 (en) Cerberus/coco derivatives and uses thereof
ES2525669T3 (es) Inhibidores de la vascularización
JP2010528016A (ja) 細胞を刺激するための方法および組成物
US8796199B2 (en) Uses of Cerberus and derivatives thereof
US20160008489A1 (en) Methods for modulating nuclear acetyltransferase activity in living brain, memory accuracy and fear generalization
AU2001233502B2 (en) Pancreatic islet cell growth factors
JP2012530735A (ja) 眼疾患の治療におけるＣＤ４４ｖ６の使用
US9180114B2 (en) Neurodegenerative diseases and methods of modeling
US20240366723A1 (en) Combination therapy for the treatment of enteric neuropathies
EP4076499B1 (en) Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
JP2002512627A (ja) Ｃｎｓ神経再生組成物及びその使用方法
WO2013021196A2 (en) Oligodendrocyte differentiation
US20230346847A1 (en) Juvenile protective factors to arrest and reverse aging in the enteric nervous system
US20250064836A1 (en) Compositions and methods for treating clostridioides difficile infections
KR100409099B1 (ko) 신경 손상 치료 기구
CN115671287A (zh) Feingold综合征Ι型治疗药物及其应用
Sivasubramanian Welfare of Japan (H14-Nano-002), by the Health and Labour

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403